Correlativ and Baker Perkins are facilitating the paradigm shift of current oral solid dosage manufacturing from batch process, to continuous. Quality-by-Design, endorsed by the FDA and implemented in the process, will result in waste, water and energy demand reductions. An intelligent process controller will automate the process and facilitate remote data access and controllability, which will cater to a more distributed workforce. The success of a continuous manufacturing line is forecasted to impart a tenfold revenue generation per annum, compared to batch. This and the inherent capital cost reduction will give us a competitive advantage, disrupting the market and propel the sector into a more environmentally sustainable future. The project is also aiming to produce an in-house particle size analyser, which can determine various parameters such as size distribution, shape morphology, and potentially material identification, for off-line as well as in-line applications. The analyser will be empowered by computer vision (machine learning) technology.